SUNHO (China) BioPharmaceutical Co., Ltd.
- Biotech or pharma, therapeutic R&D
Founded in 2018, SunHo is a Hong Kong listed biopharmaceutical company developing innovative biologics for cancers and autoimmune diseases. We have 6 clinical pipelines and also several preclinical assets, including IAH0968 (fully fucose deficient HER2 mAb), IAP0971(PD1/IL15 immunocytokine), IAE0972(EGFR/IL10 immunocytokine), IBB0979(B7H3/IL10 immunocytokine) and IBD0333(CD24/4-1BB bsAb). We also developed several preclinical assets for autoimmune, inflammation and metabolic diseases.
Our objective of attending this conference is finding partners to license out our assets. We are flexible with the territory and collaboration model.
*We will not meet service provider at this conference*
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}